Sinan Sarac: Parexel will be heavily represented at ASCO24

Sinan Sarac, Vice President of Regulatory Strategy at Parexel, shared a post on LinkedIn:

“I will be attending ASCO24 and looking forward to a couple of exciting days. Parexel will be heavily represented this year also. If you want to tap into the minds of experienced regulators from the FDA and EMA and understand how you can de-risk your drug development program and avoid regulatory pitfalls, let me know, and we can set up a meeting.”

Source: Sinan Sarac/LinkedIn

Parexel International is an American firm specializing in biopharmaceutical services, which facilitates clinical trials for pharmaceutical companies to accelerate drug approval. As the world’s second-largest clinical research organization, it has contributed to the development of around 95% of the top 200 best-selling biopharmaceuticals. Also, Parexel publishes the yearly Parexel R&D Statistical Sourcebook and oversees the Parexel Academy.